These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 16857573)

  • 21. Continuous dopamine-receptor stimulation in advanced Parkinson's disease.
    Nutt JG; Obeso JA; Stocchi F
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S109-15. PubMed ID: 11052228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
    Stocchi F; Olanow CW
    Neurology; 2004 Jan; 62(1 Suppl 1):S56-63. PubMed ID: 14718681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
    Obeso JA; Rodriguez-Oroz MC; Rodriguez M; DeLong MR; Olanow CW
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S22-32; discussion S32-4. PubMed ID: 10762129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing levodopa-induced dyskinesias.
    Olanow CW; Obeso JA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimising levodopa therapy for the management of Parkinson's disease.
    Stocchi F
    J Neurol; 2005 Oct; 252 Suppl 4():IV43-IV48. PubMed ID: 16222437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of l-DOPA-induced dyskinesia.
    Fisone G; Bezard E
    Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Sage JI; Mark MH
    Neurology; 1992 Jan; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.
    Obeso JA; Rodriguez-Oroz M; Marin C; Alonso F; Zamarbide I; Lanciego JL; Rodriguez-Diaz M
    Neurology; 2004 Jan; 62(1 Suppl 1):S17-30. PubMed ID: 14718677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology of the basal ganglia in Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE
    Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N; Grégoire L; Hadj Tahar A; Bédard PJ
    Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Continuous dopaminergic stimulation - clinical experience].
    Bogucki A; Sławek J
    Neurol Neurochir Pol; 2010; 44(4):385-95. PubMed ID: 20827612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.